Clinical Lab Industry News / Randox News

Biohit signs licensing agreement with Randox

Biohit signs licensing agreement with RandoxFinnish healthcare company Biohit Oyj and Randox Laboratories have signed a licensing agreement which gives Randox the worldwide licensing rights for GastroPanel developed by Biohit. GastroPanel developed by Biohit is a simple, non-invasive blood test for the diagnosis and screening of gastric disorders.

GastroPanel test reliably detects H. pylori infection and damage or dysfunction of the stomach mucosa (atrophic gastritis), leading to acid-free stomach. According to latest studies, non-acid stomach is a remarkable risk factor for gastric and esophageal cancer. GastroPanel is a non-invasive blood test that reliably identifies both healthy and unhealthy stomachs as well as helps to prioritize patients for further examinations.

CEO Semi Korpela, Biohit Oyj: “The combination of GastroPanel reagents with Randox analyzers opens up new distribution possibilities for both companies”.

Dr. Peter FitzGerald CBE, Managing Director of Randox: “The addition of the Biohit GastroPanel will add significantly to the range of diagnostic products we offer. Our ability to deliver these biomarkers to healthcare providers using our Biochip Array systems will enable diagnosis of gastric disorders in patients with dyspepsia ensuring appropriate further investigation and treatment and contribute to a reduction in healthcare costs. The GastroPanel will be offered in Randox analyzers used in hospitals and reference laboratories through our global distribution network in 145 countries.”



Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit’s mission is “Innovating for Health”. The purpose of the company is to take social responsibility and produce innovation, new technologies and analysis systems for use in medicine, research institutions and industry, helping to promote research and diagnostics and to improve the quality of life of people by means of preventing disease, human suffering and financial loss. We are committed to social responsibility and it is our duty to spread knowledge about the Group I human carcinogen, acetaldehyde, and innovate and develop the marketing and availability of our products and services. Biohit is headquartered in Helsinki, Finland and its subsidiaries are located in China, Italy and the United Kingdom. Since 1999, Biohit’s Series B shares (BIOBV) have been listed in the NASDAQ OMX Helsinki Oy Small cap/Healthcare sector.


Randox is committed to developing revolutionary diagnostic solutions, improving healthcare globally. With over 30 years’ experience in the industry, Randox can provide the perfect solution for your laboratory needs. The Randox product portfolio is extensive and includes: clinical chemistry and immunoassay analysers, high quality reagents, quality control material and the largest global EQA scheme in the world; RIQAS. The range also extends into molecular diagnostics and life sciences. Developed by Randox, Biochip Array Technology offers a unique multiplexing solution for efficient, reliable and cost-effective testing. Visit Randox to find out how to revolutionise your laboratory with innovative diagnostic solutions.

Leave a Reply

Your email address will not be published. Required fields are marked *